文献速递白血病

MCL1抑制剂MIK665在儿童急性髓系白血病临床前模型中显示强效治疗活性

The myeloid cell leukaemia-1 inhibitor MIK665 is a potent therapy in preclinical models of paediatric acute myeloid leukaemia.
PubMed 文献 · Br J Haematol · 2026-06-04

儿童急性髓系白血病(AML)生存率已进入平台期,亟需靶向治疗。该临床前研究首次评估BH3模拟物MIK665(靶向MCL1)对多种AML细胞系及儿童AML患者来源异种移植(PDX)模型的疗效。结果显示MIK665单药有效,对部分PDX模型在体外和体内均有显著活性,且对心脏组织病理生理影响轻微,支持其以精准医学方式推进临床。

要点

  • MIK665作为单药对多种儿童AML细胞系显示有效。
  • MIK665对部分儿童AML PDX模型体外和体内均有显著活性。
  • MIK665对心脏组织病理生理影响轻微,支持临床推进。

核心结论

  • MIK665在儿童AML临床前模型中显示强效单药活性,支持以精准医学方式推进临床。

研究设计与样本

  • 临床前研究:评估MIK665对多种AML细胞系及儿童AML患者来源异种移植(PDX)模型(体外和体内)的疗效。

主要发现

  • MIK665作为单药对多种AML细胞系有效。
  • MIK665对部分儿童AML PDX模型在体外和体内均有显著活性。
  • MIK665对心脏组织病理生理影响轻微。

临床怎么用

  • 支持MIK665以精准医学方式推进儿童AML临床开发。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Paediatric acute myeloid leukaemia (AML) remains a deadly disease, with survival rates reaching a plateau despite treatment with high-intensity chemotherapy. Recent advancements in therapeutic strategies, such as targeted therapies to inhibit AML dependencies, have aimed to improve outcomes. The evasion of apoptosis, regulated by the B-cell lymphoma 2 (BCL2) family of proteins, is a key feature of cancer progression and treatment resistance. Bcl-2 homology domain 3 (BH3) mimetics, such as venetoclax (ABT-199), which targets BCL2, have shown promising activity in AML. This study investigates for the first time the therapeutic potential of MIK665, a BH3 mimetic targeting myeloid cell leukaemia-1 (MCL1), in paediatric AML. We evaluated the efficacy of MIK665 against a diverse panel of AML cell lines and demonstrated its effectiveness as a single-agent treatment. Additionally, MIK665 showed significant activity against a subset of paediatric AML patient-derived xenografts (PDXs) in both ex vivo and in vivo experiments, with minimal impact on cardiac tissue pathophysiology. These findings strongly support the clinical advancement of MIK665 for paediatric AML treatment in a precision medicine approach.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Connerty P, Colgan JN, El-Najjar F, et al. The myeloid cell leukaemia-1 inhibitor MIK665 is a potent therapy in preclinical models of paediatric acute myeloid leukaemia. Br J Haematol. 2026. PMID: 42237892. doi:10.1111/bjh.70596

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。